Frontlight ResearchEarly access
Active, not recruitingPhase 1
A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants
Key facts
- Who runs it
- Sanofi-Aventis Recherche & Developpement
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 24 people, planned
- Started
- 30 Jun 2026
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Record updated
- 20 October 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women only
- Healthy volunteers
- Can take part
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 20 October 2026